Global Injectable Drug Delivery Market Reports, Industry Trends and Forecast, Outlook 2024 Insights


@databridgemarketresearch


The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Global Injectable Drug Delivery Market, By Type (Devices {Conventional Injection, Self-Injection}, Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration  (Skin, Circulatory, Organs, Central Nervous System), End User  (Hospitals & Clinics, Home Care Settings, Research Laboratories,  Pharma & Biotech Companies), Geography (North America,  Europe, Asia-Pacific, South America, Middle East Africa) – Industry Trends and Forecast to 2024


The Global injectable drug delivery Market is expected to reach USD 789.7 billion by 2024 from USD 330.6 billion in 2016, at a CAGR of 11.5% in the forecast period 2017 to 2024. 



Segmentation:


By Type (Devices {Conventional Injection, Self-Injection},  Formulations {Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations}, Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User (Hospitals & Clinics, Home Care Settings, Research Laboratories, Pharma& Biotech Companies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa)


Drivers:


Some of the major factors driving the market for injectable drug delivery market, such as increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain). These factors increase the demand for devices such as safety syringes, prefilled syringes, and auto-disabled syringes. Increasing prevalence of chronic diseases, rising demand for self-injection devices, growth of the biologics, and technological advancements are the major factors driving the growth of the injectable drug delivery market.GROWING GERIATRIC POPULATION


RISING CASES OF CHRONIC DISEASES


In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) across the globe has increased considerably over a period of time. The rapidly increasing aging population and the subsequent rise in chronic conditions are major factors driving the demand forself-injection devices and cost of healthcare.


RISING DEMAND OF SELF-INJECTION DEVICES


Self-injection devices are a combination of automatic injection systems with audio-visual guides for surgeries; this includes safety syringes and hidden needles, among others. It has also emerged as one of the fastest growing areas for unit dose medication in order to minimize drug waste and increase product lifespan.


GROWTH OF BIOLOGICS MARKET


The biologics market is considered to be the fastest-growing sector of the pharmaceutical industry. Biologics are large molecules that require to be administered by injections given their size and profile. Biologics are medicines made from living cells through highly complex manufacturing processes used to prevent, treat, diagnose, or cure a variety of serious and chronic illnesses including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases.


TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET


The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches in order to improve the convenience and ease of administration of parenteral therapeutics.



Based on geography, the market is segmented into five geographical regions:


·         North America

·         Europe

·         Asia-Pacific

·         South America

·         Middle East and Africa.


The geographical regions are further segmented into 29 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.


Some of the major players operating in this market are


·         Baxter International, Inc.

·         Becton Dickinson and Company

·         Gerresheimer AG

·         Pfizer, Inc.

·         Schott AG

·         Alkermes Plc.

·         Eli Lilly and Company

·         Sandoz

·         Terumo Corporation

·         Teva Pharmaceuticals Industries Ltd.

·         Bespak

·         Antares Pharma

·         Elcam Medical

·         Haselmeier

·         Mylan N.V.

·         Novo Nordisk

·         Owen Mumford Ltd

·         Sanofi

·         West Pharmaceutical Services, Inc

·         Ypsomed Holding AG.



Table Of Content:


1. INTRODUCTION

       1.1. OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET

       1.2. MARKET SEGMENTATION & COVERAGE

                1.2.1. CURRENCY AND PRICING

                1.2.2. LIMITATION

                1.2.3. STAKEHOLDERS

2. RESEARCH METHODOLOGY

       2.1. KEY TAKEAWAYS

       2.2. ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE

                2.2.1. MARKET CRACKDOWN APPROACH

                2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS

                2.2.3. DATA TRIANGULATION

                2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES

                2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES

                2.2.6. PORTER’S FIVE FORCES MATRIX

       2.3. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT

       2.4. ASSUMPTIONS

3. MARKET LANDSCAPE SUMMARY

4. PREMIUM INSIGHTS

       4.1. OVERVIEW

       4.2. INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS

       4.3. MARKET OVERVIEW

                4.3.1. DRIVERS

                           4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES

                           4.3.1.2. INCRESING DEMAND OF SELF INJECTION DEVICES

                           4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET

                           4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET

                4.3.2. RESTRAINTS

                4.3.3. OPPORTUNITIES

                           4.3.3.1. INCRESING DEMAND FOR GENERIC INJECTABLES

                4.3.4. THREATS

                           4.3.4.1. PRODUCT RECALLS

                           4.3.4.2. REGULATORY HURDLES

                           4.3.4.3. STABILITY OF PRODUCTS

                           4.3.4.4. STERILITY OF INJECTIONS

                           4.3.4.5. GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES

       4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5. INJECTABLE DRUG DELIVERY MARKET, BY TYPE

       5.1. OVERVIEW

       5.2. INJECTABLE DRUG DELIVERY DEVICES

       5.3. INJECTABLE DRUG DELIVERY FORMULATIONS

6. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

       6.1. OVERVIEW

       6.2. CONVENTIONAL INJECTION DEVICES

                6.2.1. BY MATERIAL

                           6.2.1.1. GLASS

                           6.2.1.2. PLASTIC

                6.2.2. BY PRODUCT

                           6.2.2.1. EMPTY SYRINGES

                           6.2.2.2. PREFILLED SYRINGES

                6.2.3. BY USABLITY

                           6.2.3.1. REUSABLE SYRINGES

                           6.2.3.2. DISPOSABLE SYRINGES

       6.3. SELF INJECTION DEVICES

                6.3.1. NEEDLE FREE INJECTORS

                           6.3.1.1. BY PRODUCT

                                         6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS

                                         6.3.1.1.2. PREFILLED NEEDLE FREE INJECTORS

                            6.3.1.2. BY TECHNOLOGY

                                         6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS

                                         6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS

                                         6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS

                           6.3.1.3. BY USABILITY

                                         6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS

                                         6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS

                6.3.2. AUTOINJECTORS

                           6.3.2.1. BY PRODUCT

                                         6.3.2.1.1. EMPTY AUTOINJECTORS

                                         6.3.2.1.2. PREFILLED AUTOINJECTORS

                           6.3.2.2. BY TECHNOLOGY

                                         6.3.2.2.1. AUTOMATED AUTOINJECTORS

                                         6.3.2.2.2. MANUAL AUTOINJECTORS

                           6.3.2.3. BY DESIGN

                                         6.3.2.3.1. STANDARDIZED AUTOINJECTORS

                                         6.3.2.3.2. CUSTOMIZED AUTOINJECTORS

                           6.3.2.4. BY USABILITY

                                         6.3.2.4.1. REUSABLE AUTOINJECTORS

                                         6.3.2.4.2. DISPOSABLE AUTOINJECTORS

                6.3.3. PEN INJECTORS

                           6.3.3.1. BY PRODUCT

                                         6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS

                                         6.3.3.1.2. DUAL CHAMBERED PEN INJECTORS

                           6.3.3.2. BY DESIGN

                                         6.3.3.2.1. STANDARDIZED PEN INJECTORS

                                         6.3.3.2.2. CUSTOMIZED PEN INJECTORS

                           6.3.3.3. BY USABILITY

                                         6.3.2.3.1. REUSABLE PEN INJECTORS

                                         6.3.2.3.2. DISPOSABLE PEN INJECTORS

                6.3.4. WEARABLE INJECTORS

                6.3.5. OTHER INJECTABLE DEVICES

7. INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE

       7.1. OVERVIEW

       7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS

                7.2.1. SOLUTIONS

                7.2.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS

                7.2.3. SUSPENSIONS

                7.2.4. EMULSIONS

       7.3. NOVEL DRUG DELIVERY FORMULATIONS

                7.3.1. COLLOIDAL DISPERSIONS

                           7.3.1.1. LIPOSOMES

                           7.3.1.2. NIOSOMES

                           7.3.1.3. POLYMERIC MIXED MICELLES

                           7.3.1.4. NANOPARICLES

                                         7.3.1.4.1. NANOSUSPENSIONS

                                         7.3.1.4.2. NANOEMULSIONS/MICROEMULSIONS

                                         7.3.1.4.3. SOLID LIPID NANOPARTICLES

                7.3.2. MICROPARTICLES

                           7.3.2.1. MICROSPHERES

                           7.3.2.2. MICROCAPSULES

                7.3.3. LONG ACTING INJECTION FORMULATIONS

8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS

       8.1. OVERVIEW

       8.2. AUTOIMMUNE DISEASES

                8.2.1. RHEUMATOID ARTHRITIS

                8.2.2. MULTIPLE SCLEROSIS

                8.2.3. CHRON’S DISEASE

                8.2.4. PSORIASIS

                8.2.5. OTHER AUTOIMMUNE DISEASES

       8.3. HORMONAL DISORDERS

                8.3.1. DIABETES

                8.3.2. ANEMIA

                8.3.3. REPRODUCTIVE HEALTH DISEASE

                8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY

                8.3.5. OSTEOPOROSIS

                8.3.6. GROWTH HORMONE DEFICIENCY (GHD)

       8.4. ORPHAN DISEASES

       8.5. ONCOLOGY

       8.6. OTHERS

                8.6.1. PAIN MANAGEMENT

                8.6.2. ALERGY TREATMENT

                8.6.3. AESTHETIC TREATMENTS

                8.6.4. HEPATITIS C

                8.6.5. HEMOPHILIA

9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

       9.1. OVERVIEW

       9.2. CURATIVE CARE

       9.3. IMMUNIZATIONS

       9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)

10. INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

       10.1. OVERVIEW

       10.2. SKIN

       10.3. CIRCULATORY/MUSKOSKELETAL

       10.4. ORGANS

       10.5. CENTRAL NERVOUS SYSTEM

11. INJECTABLE DRUG DELIVERY MARKET, BY END USER

       11.1. OVERVIEW

       11.2. HOSPITALS AND CLINICS

       11.3. HOME HEALTHCARE SETTINGS

       11.4. RESEARCH LABORATORIES

       11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES

       11.6. OTHER END USERS

12. INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

       12.1. COUNTRYWISE  INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

                12.1.1. NORTH AMERICA

                                         12.1.1.1. U.S.

                                         12.1.1.2. CANADA

                                          12.1.1.3. MEXICO

                12.1.2. EUROPE

                                         12.1.2.1. GERMANY

                                         12.1.2.2. FRANCE

                                         12.1.2.3. U.K.

                                         12.1.2.4. ITALY

                                         12.1.2.5. SPAIN

                                         12.1.2.6. RUSSIA

                                         12.1.2.7. TURKEY

                                          12.1.2.8. BELGIUM

                                         12.1.2.9. NETHERLANDS

                                          12.1.2.7. SWITZERLAND

                                         12.1.2.8. REST OF EUROPE

                12.1.3. ASIA-PACIFIC (APAC)

                                         12.1.3.1. JAPAN

                                         12.1.3.2. CHINA

                                         12.1.3.3. SOUTH KOREA

                                         12.1.3.4. INDIA

                                         12.1.3.5. AUSTRALIA

                                         12.1.3.6. SINGAPORE

                                         12.1.3.7. THAILAND

                                         12.1.3.8. MALAYSIA

                                         12.1.3.9. INDONESIA

                                         12.1.3.10. PHILIPPINES

                                         12.1.3.11. REST OF APAC

                12.1.4. LATIN AMERICA

                                         12.1.4.1. BRAZIL

                                         12.1.4.2. REST OF LATIN AMERICA

                12.1.5. MIDDLE EAST AND AFRICA

                                         12.1.5.1. SOUTH AFRICA

                                         12.1.5.2. REST OF MIDDLE EAST AND AFRICA

       12.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

13. INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

       13.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.6. MIDDLE EAST AND AFRICA  INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS

       13.7. MERGERS & ACQUISITIONS

       13.8. NEW PRODUCT DEVELOPMENT & APPROVALS

       13.9. EXPANSIONS

       13.10. REGULATORY CHANGES

       13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

14. INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES

       14.1. BAXTER INTERNATIONAL, INC.

                14.1.1. OVERVIEW

                14.1.2. SWOT ANALYSIS

                14.1.3. PRODUCT PORTFOLIO

                14.1.4. REVENUE ANALYSIS

                14.1.5. ANALYSTS VIEW

       14.2. BECTON, DICKINSON AND COMPANY

                14.2.1. OVERVIEW

                14.2.2. SWOT ANALYSIS

                14.2.3. PRODUCT PORTFOLIO

                14.2.4. REVENUE ANALYSIS

                14.2.5. ANALYSTS VIEW

       14.3. GERRESHEIMER, AG

                14.3.1. OVERVIEW

                14.3.2. SWOT ANALYSIS

                14.3.3. PRODUCT PORTFOLIO

                14.3.4. REVENUE ANALYSIS

                14.3.5. ANALYST VIEW

       14.4. PFIZER, INC.

                14.4.1. OVERVIEW

                14.4.2. SWOT ANALYSIS

                14.4.3. PRODUCT PORTFOLIO

                14.4.4. REVENUE ANALYSIS

                14.4.5. ANALYSTS VIEW

       14.5. SCHOTT AG

                14.5.1. OVERVIEW

                14.5.2. SWOT ANALYSIS

                14.5.3. PRODUCT PORTFOLIO

                14.5.4. REVENUE ANALYSIS

                14.5.5. ANALYSTS VIEW

       14.6. ALKERMES PLC

                14.6.1. OVERVIEW

                14.6.2. SWOT ANALYSIS

                14.6.3. PRODUCT PORTFOLIO

                14.6.4. REVENUE ANALYSIS

                14.6.5. ANALYSTS VIEW

       14.7. ELI LILLY AND COMPANY

                14.7.1. OVERVIEW

                14.7.2. SWOT ANALYSIS

                14.7.3. PRODUCT PORTFOLIO

                14.7.4. REVENUE ANALYSIS

                14.7.5. ANALYSTS VIEW

       14.8. SANDOZ

                14.8.1. OVERVIEW

                14.8.2. SWOT ANALYSIS

                14.8.3. PRODUCT PORTFOLIO

                14.8.4. REVENUE ANALYSIS

                14.8.5. ANALYSTS VIEW

       14.9. TERUMO CORPORATION

                14.9.1. OVERVIEW

                14.9.2. SWOT ANALYSIS

                14.9.3. PRODUCT PORTFOLIO

                14.9.4. REVENUE ANALYSIS

                14.9.5. ANALYSTS VIEW

       14.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.

                14.10.1. OVERVIEW

                14.10.2. SWOT ANALYSIS

                14.10.3. PRODUCT PORTFOLIO

                14.10.4. REVENUE ANALYSIS

                14.10.5. ANALYSTS VIEW

15. APPENDIX

       15.1. RELATED REPORTS

       15.2. CUSTOMIZABLE OPTIONS

       15.3. SOURCE SHEET

       15.4. BIBLIOGRAPHY

16. ABOUT DATA BRIDGE MARKET RESEARCH

  

Related Report


Global Hemostats Market- Trends and Forecast to 2024


Global Hemostats Market, By Product Type (Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based Hemostat), By Indication (Wound Closure, Surgery), By End-User (Hospitals, Clinics, Ambulatory Centers, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Trends and Forecast to 2024



About Data Bridge Market Research:


Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Contact:


Ankit Singh

Data Bridge Market Research

Tel: +1-888-387-2818

Visit Blog http://databridgemarketresearch.com/blog/

Economy News